Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volume – Time to Buy?

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) shares saw strong trading volume on Monday . 5,485 shares changed hands during trading, a decline of 39% from the previous session’s volume of 8,961 shares.The stock last traded at $16.57 and had previously closed at $17.75.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Weiss Ratings reissued a “hold (c-)” rating on shares of Pharming Group in a research report on Tuesday, November 25th. Zacks Research raised Pharming Group from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, Pharming Group has a consensus rating of “Buy” and an average price target of $30.00.

Pharming Group Price Performance

The company has a debt-to-equity ratio of 0.35, a current ratio of 3.16 and a quick ratio of 2.39. The stock has a market capitalization of $1.12 billion and a price-to-earnings ratio of -1,633.37. The company has a 50-day simple moving average of $15.01 and a two-hundred day simple moving average of $12.86.

Pharming Group (NASDAQ:PHAR) last posted its earnings results on Thursday, November 6th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.05 by $0.05. The firm had revenue of $97.30 million for the quarter, compared to analysts’ expectations of $98.22 million. Pharming Group had a return on equity of 0.46% and a net margin of 0.30%. Pharming Group has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Pharming Group N.V. Sponsored ADR will post -0.2 earnings per share for the current year.

Institutional Trading of Pharming Group

A hedge fund recently bought a new stake in Pharming Group stock. EverSource Wealth Advisors LLC bought a new position in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 2,979 shares of the company’s stock, valued at approximately $32,000. 0.03% of the stock is owned by institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.